Joseph Matovu KB
ID: UNCST-2020-R014654
|
Reducing hazardous alcohol use and optimizing treatment as prevention among men living with HIV in risk environments
REFNo: HS5558ES
Understand barriers and facilitators in the inner and outer context for implementing the components of Kisoboka within the routine clinical setting to inform future widespread implementation guided by the Exploration, Preparation, Implementation and Sustainment (EPIS) framework and documentation of intervention and implementation costs. ,Assess the impact of the Kisoboka intervention and its components on measures of psychological, physical, and socioeconomic well-being that capture frequent comorbidities of people living with HIV and are associated with achieving successful treatment as prevention,Determine the efficacy of the Kisoboka intervention and its components on alcohol and HIV outcomes among hazardously drinking men living with HIV in Uganda in a 2x2 factorial RCT. ,Assess the efficacy of Kisoboka and its components (BE & MI) to gain insight into Kisoboka’s potential effect, determine if BE and MI interact and examine barriers and facilitators for implementing Kisoboka within routine clinical settings to inform future widespread implementation.,
|
Uganda |
2025-02-14 15:19:41 |
2028-02-14 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
A Prospective, Clinical Trial Examining the Immune Response of Participants Receiving Modified Vaccinia Ankara (MVA) Vaccine in Africa,”-Mpox Vax Africa
REFNo: HS5575ES
To determine:
the development of MVA-BN-specific antibodies at week 6 post-first vaccination with MVA-BN in
a population recruited in Africa, and compare to a population recruited in Europe.
Durability of MVA-BN-specific antibodies at week 24 post-first vaccination with MVA-BN.
? Factors associated with MVA-BN-specific antibody responses at week 48 post-first
vaccination with MVA-BN.
? Durability of MVA-BN-specific antibodies at week 48 post-first vaccination between a
population recruited in Africa and a population recruited in Europe.
? Durability of MVA-BN-specific antibodies at week 48 post-first vaccination with MVA-BN in
understudied populations (women and PLWH).
? Prevalence of asymptomatic seroconversion to mpox by week 48 post-first vaccination
|
Uganda |
2025-02-08 13:35:10 |
2028-02-08 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
.jpg)
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
THE SECOND UGANDA TB PREVALENCE SURVEY (TBPS2)
REFNo: HS5269ES
Estimating the sizes of key and vulnerable TB populations as defined in the national gender and key and vulnerable populations assessment report nationally and sub nationally,Evaluating factors associated with TB including HIV, diabetes, undernutrition, tobacco smoking, alcohol ab use, and socio-economic status,,Updating population-based estimates of TB burden using results from the prevalence survey ,Assessing healthcare-seeking behaviors and understand where individuals with TB symptoms seek medical care,The secondary objectives of TBPS2 in Uganda encompass: The prevalence of symptoms suggestive of pulmonary tuberculosis (PTB) and determining radiological abnormalities among individuals aged ?15 years, ,The primary objective is to determine the national and subnational prevalence of bacteriologically confirmed pulmonary TB among the general population aged ?15 years,The goal of the survey is to enable the country (MOH/NTLP and partners) to gain a better understanding of the current burden of TB, health-seeking behavior and health system response in order to identify ways of improving TB programming towards ending TB in the country.,
|
Uganda |
2025-02-07 18:27:07 |
2028-02-07 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
DANIEL KIIZA
ID: UNCST-2024-R004044
|
Retrospective chart review of patients with Laboratory-Confirmed Sudan Virus Disease Hospitalized in Two Ebola Disease Treatment Units in Uganda (September 2022 to January 2023)
REFNo: HS5541ES
To evaluate the safety and clinical course of patients receiving investigational treatments for SVD,To identify host and disease factors associated with outcomes from SVD,To characterize the natural history and outcomes of Sudan virus disease (SVD) among hospitalized patients with RT-PCR detected Orthoebolavirus sudanense (SUDV) RNA,
|
Uganda |
2025-02-07 18:10:59 |
2028-02-07 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Clare Bangirana Ahabwe
ID: UNCST-2021-R012842
|
AN OUTCOME RESEARCH ON THE WESTERN UGANDA BANTWANA PROGRAM ON VIOLENCE AGAINST CHILDREN IN SCHOOLS AND SURROUNDING COMMUNITIES (VACiSC) IN THE THREE DISTRICTS OF KABAROLE, KYENJOJO and BUNYANGABU
REFNo: SS3625ES
The study aims to assess the effectiveness of the Western Uganda Bantwana Program (WUBP) in preventing and responding to Violence Against Children (VAC), including child sexual abuse (CSA), in schools and surrounding communities in the three Districts of Kabarole, Kyenjojo, and Bunyangabu
Specific Objectives
1. To measure the change in knowledge, attitude and practices on risks exposures to VACiSC including CSA with focus on prevention and response among children, young adults, caregivers and teachers.
2. To assess how the WUBP aligned to the needs of communities and existing practices (structures and approaches) on prevention and response to VACiSC including CSA.
3. To evaluate the role of caregivers, teachers, para-social workers, and community leaders in creating and maintaining safe environments for children.
|
Uganda |
2025-02-07 18:09:14 |
2028-02-07 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|